QMA

Regeneron Pharmaceuticals, Inc. (REGN) — QMA analysis

Sector: Healthcare · Market cap: $80.9B · Price: $805.02 · Data as of 2026-10-24

61
/100
B
Composite grade
Higher score than 93% of 22,734 tracked stocks

Regeneron Pharmaceuticals, Inc. has an above-average composite score of 61/100, higher score than 93% of 22,734 tracked stocks. The highest-scoring layer is Catalysts; the lowest is Insider activity.

Analytical score, not investment advice. No score is an instruction or a guarantee. Past performance ≠ future results.
Share this analysis
𝕏in

What 13 data layers say about REGN

The composite fuses insiders, congressional trades, institutional 13F positions, fundamentals, momentum, seasonality and more into a single number.

LayerScore
Fundamental value (FVS)73/100
Earnings quality (EQS)55/100
Technical trend (TSS)59/100
Relative strength (RS)39/100
Momentum (USS)34/100
Insider activity (IAS)10/100
Off-exchange trading (FINRA) / large flows (WHS)37/100
Institutional 13F (IFS)53/100
Options flow (OFS)70/100
Congressional trades (PTS)35/100
News sentiment (NSS)59/100
Analysts / transcripts (ATS)70/100
Catalysts (XS)93/100

What does the QMA model currently show for Regeneron Pharmaceuticals, Inc.?

The composite score is an entry point, not a signal. What matters is layer confluence — whether they point the same direction.

For REGN the layers diverge — some score high (Catalysts), others low (Insider activity). The divergence is itself information: the model does not give a clear-cut picture. The score is an input into your own research, not a recommendation.

REGN insider & smart money activity

Over the recent period we record 5 reported insider purchases and 10 sales for REGN: mixed picture. A description of the data layer, not an instruction.

REGN seasonality

The historically strong window for REGN was July 1–28 with a hit rate of 76% and an average move of 7.8% (21 years of history).

Historical data does not guarantee future results.

REGN dividend

Regeneron Pharmaceuticals, Inc. currently carries a dividend yield of 0.46% and has paid for 2 years in a row.

How REGN compares

Similar stocks from the same sector:

Frequently asked questions

What is the composite score for REGN stock?

61/100 (grade B) as of 2026-10-24, fusing 13 data layers. An analytical score, not advice.

Are insiders buying REGN stock?

Over the recent period, reported: purchases 5, sales 10 (purchases $7.97M, sales $21.8M). Insider activity: mixed picture — a description of reported data, not a trade instruction.

Where can I see live REGN data?

Live REGN data and the full screener are part of full access. Registration is free with no card — trial full access, then the free plan with a delayed data sample.

Explore more — for free

The REGN score is just the start. Keep going free in the QMA magazine — analysis, tools and learning with no payment up front.

Free registration, no card — trial full access, then the free plan

Want the full REGN analysis with all layers and live data? Open REGN detail →

Data from SEC and public markets. QMA is an analytical tool, not a registered investment advisor. No content on this page is investment advice or an instruction to buy or sell. Past performance does not guarantee future results.

⚠️ Important Notice: QMA is an analytical and educational tool, not investment advice. Scores, detections and ratings are descriptive, not buy/sell instructions. QMA is not a registered investment advisor (SEC / FINRA / MiFID II / ČNB). Consult a licensed financial advisor before any investment. Past performance does not guarantee future results; all investments carry the risk of capital loss.

Operator: Jaroslav Vojtášek · IČO: 48783447 · Place of business: U Jízdárny 577, 747 64 Velká Polom, Czech Republic · Register: Sole trader registered in the Czech Trade Licensing Register · E-mail: [email protected]